Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye

Gail Torkildsen,1 Mile Brujic,2 Michael S Cooper,3 Paul Karpecki,4 Parag Majmudar,5 William Trattler,6 Meryl Reis,7 Joseph B Ciolino1,8 1Andover Eye Clinic, Andover MA, 2Premier Vision Group, Bowling Green, OH, 3Windam Eye Group, Willimantic, CT, 4Gaddie Eye Center, Louisville KY, 5Chicago Cornea...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Torkildsen G, Brujic M, Cooper MS, Karpecki P, Majmudar P, Trattler W, Reis M, Ciolino JB
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	artificial tears dry eye tear film visual function blurred vision Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/7e2588f693364306a02d15e1c3bd546a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7e2588f693364306a02d15e1c3bd546a
record_format	dspace
spelling	oai:doaj.org-article:7e2588f693364306a02d15e1c3bd546a2021-12-02T07:35:39ZEvaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye1177-5483https://doaj.org/article/7e2588f693364306a02d15e1c3bd546a2017-10-01T00:00:00Zhttps://www.dovepress.com/evaluation-of-a-new-artificial-tear-formulation-for-the-management-of--peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Gail Torkildsen,1 Mile Brujic,2 Michael S Cooper,3 Paul Karpecki,4 Parag Majmudar,5 William Trattler,6 Meryl Reis,7 Joseph B Ciolino1,8 1Andover Eye Clinic, Andover MA, 2Premier Vision Group, Bowling Green, OH, 3Windam Eye Group, Willimantic, CT, 4Gaddie Eye Center, Louisville KY, 5Chicago Cornea Consultants, Chicago IL, 6Center For Excellence in Eye Care, Miami, FL, 7Rohto Mentholatum Research Laboratories, Horsham, PA, 8Massachusetts Eye and Ear Infirmary, Boston MA, USA Purpose: Artificial tears are the first line of therapy for dry eye disease (DED) and are also the most frequently used treatment approach for this common condition. Despite this, there are few published studies that directly compare the effectiveness of different drop preparations, especially those formulated specifically for dry eye. In this study, we tested a new artificial tear product, Rohto® Dry-Aid™, for its ability to relieve the signs and symptoms of DED. The study used a second drop, Systane® Ultra, as a positive comparator.Materials and methods: This was a prospective, single-center, open-label, parallel-group study comparing the effects of the two products when used continuously over ~30 days (Clinical Trials registration number NCT03183089). Subjects were randomly assigned to one of the two test groups and were monitored 2 and 4 weeks after enrollment. Efficacy endpoints included ocular staining, visual function, and ocular discomfort.Results: Treatment groups had similar ocular staining and ocular comfort scores, and both showed statistically significant ocular discomfort score improvement. Subjects in the Rohto group reported significant improvements in visual tasking activities such as watching television and driving at night. There was also a tendency for diary symptom scores to worsen from morning to evening in the Systane group, but not in the Rohto group; this trend was not significant, but warrants further study.Conclusion: The two products, Rohto Dry-Aid and Systane Ultra, elicited comparable effects on the signs and symptoms of DED. While both products are designed to provide long-lasting relief, subjects in the Rohto group experienced a superior relief from discomfort associated with visual tasking activities and daily diaries, indicating that the Rohto drops may provide a longer duration of symptomatic relief over the course of the day. Keywords: artificial tears, dry eye, ocular surface, visual tasking, blurred visionTorkildsen GBrujic MCooper MSKarpecki PMajmudar PTrattler WReis MCiolino JBDove Medical Pressarticleartificial tearsdry eyetear filmvisual functionblurred visionOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 1883-1889 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	artificial tears dry eye tear film visual function blurred vision Ophthalmology RE1-994
spellingShingle	artificial tears dry eye tear film visual function blurred vision Ophthalmology RE1-994 Torkildsen G Brujic M Cooper MS Karpecki P Majmudar P Trattler W Reis M Ciolino JB Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye
description	Gail Torkildsen,1 Mile Brujic,2 Michael S Cooper,3 Paul Karpecki,4 Parag Majmudar,5 William Trattler,6 Meryl Reis,7 Joseph B Ciolino1,8 1Andover Eye Clinic, Andover MA, 2Premier Vision Group, Bowling Green, OH, 3Windam Eye Group, Willimantic, CT, 4Gaddie Eye Center, Louisville KY, 5Chicago Cornea Consultants, Chicago IL, 6Center For Excellence in Eye Care, Miami, FL, 7Rohto Mentholatum Research Laboratories, Horsham, PA, 8Massachusetts Eye and Ear Infirmary, Boston MA, USA Purpose: Artificial tears are the first line of therapy for dry eye disease (DED) and are also the most frequently used treatment approach for this common condition. Despite this, there are few published studies that directly compare the effectiveness of different drop preparations, especially those formulated specifically for dry eye. In this study, we tested a new artificial tear product, Rohto® Dry-Aid™, for its ability to relieve the signs and symptoms of DED. The study used a second drop, Systane® Ultra, as a positive comparator.Materials and methods: This was a prospective, single-center, open-label, parallel-group study comparing the effects of the two products when used continuously over ~30 days (Clinical Trials registration number NCT03183089). Subjects were randomly assigned to one of the two test groups and were monitored 2 and 4 weeks after enrollment. Efficacy endpoints included ocular staining, visual function, and ocular discomfort.Results: Treatment groups had similar ocular staining and ocular comfort scores, and both showed statistically significant ocular discomfort score improvement. Subjects in the Rohto group reported significant improvements in visual tasking activities such as watching television and driving at night. There was also a tendency for diary symptom scores to worsen from morning to evening in the Systane group, but not in the Rohto group; this trend was not significant, but warrants further study.Conclusion: The two products, Rohto Dry-Aid and Systane Ultra, elicited comparable effects on the signs and symptoms of DED. While both products are designed to provide long-lasting relief, subjects in the Rohto group experienced a superior relief from discomfort associated with visual tasking activities and daily diaries, indicating that the Rohto drops may provide a longer duration of symptomatic relief over the course of the day. Keywords: artificial tears, dry eye, ocular surface, visual tasking, blurred vision
format	article
author	Torkildsen G Brujic M Cooper MS Karpecki P Majmudar P Trattler W Reis M Ciolino JB
author_facet	Torkildsen G Brujic M Cooper MS Karpecki P Majmudar P Trattler W Reis M Ciolino JB
author_sort	Torkildsen G
title	Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye
title_short	Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye
title_full	Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye
title_fullStr	Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye
title_full_unstemmed	Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye
title_sort	evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/7e2588f693364306a02d15e1c3bd546a
work_keys_str_mv	AT torkildseng evaluationofanewartificialtearformulationforthemanagementoftearfilmstabilityandvisualfunctioninpatientswithdryeye AT brujicm evaluationofanewartificialtearformulationforthemanagementoftearfilmstabilityandvisualfunctioninpatientswithdryeye AT cooperms evaluationofanewartificialtearformulationforthemanagementoftearfilmstabilityandvisualfunctioninpatientswithdryeye AT karpeckip evaluationofanewartificialtearformulationforthemanagementoftearfilmstabilityandvisualfunctioninpatientswithdryeye AT majmudarp evaluationofanewartificialtearformulationforthemanagementoftearfilmstabilityandvisualfunctioninpatientswithdryeye AT trattlerw evaluationofanewartificialtearformulationforthemanagementoftearfilmstabilityandvisualfunctioninpatientswithdryeye AT reism evaluationofanewartificialtearformulationforthemanagementoftearfilmstabilityandvisualfunctioninpatientswithdryeye AT ciolinojb evaluationofanewartificialtearformulationforthemanagementoftearfilmstabilityandvisualfunctioninpatientswithdryeye
_version_	1718399347722289152

Evaluation of a new artificial tear formulation for the management of tear film stability and visual function in patients with dry eye

Ejemplares similares